DK3149001T3 - Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere - Google Patents

Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere Download PDF

Info

Publication number: DK3149001T3
Authority: DK; Denmark
Prior art keywords: pyrazolopyrimidine derivatives; malt1 inhibitors; new; new pyrazolopyrimidine; malt1
Prior art date: 2014-05-28

Application number

DK15733899.7T

Other languages

English (en)

Inventor

Soldermann Carole Pissot

Jean Quancard

Achim Schlapbach

Oliver Simic

Marina Tintelnot-Blomley

Thomas Zoller

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-28

Filing date

2015-05-27

Publication date

2019-07-22

2015-05-27 Application filed by Novartis Ag filed Critical Novartis Ag

2019-07-22 Application granted granted Critical

2019-07-22 Publication of DK3149001T3 publication Critical patent/DK3149001T3/da

Links

229940122339 MALT1 inhibitor Drugs 0.000 title 1
OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK15733899.7T 2014-05-28 2015-05-27 Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere DK3149001T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14170408		2014-05-28
PCT/IB2015/053975 WO2015181747A1 (en)	2014-05-28	2015-05-27	Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors

Publications (1)

Publication Number	Publication Date
DK3149001T3 true DK3149001T3 (da)	2019-07-22

Family

ID=50828759

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15733899.7T DK3149001T3 (da)	2014-05-28	2015-05-27	Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere

Country Status (36)

Country	Link
US (2)	US9815842B2 (da)
EP (1)	EP3149001B1 (da)
JP (1)	JP6545197B2 (da)
KR (1)	KR20170007311A (da)
CN (1)	CN106170489B (da)
AP (1)	AP2016009487A0 (da)
AR (1)	AR100645A1 (da)
AU (1)	AU2015265478B2 (da)
BR (1)	BR112016024545A2 (da)
CA (1)	CA2945077A1 (da)
CL (1)	CL2016002942A1 (da)
CR (1)	CR20160548A (da)
CU (1)	CU24393B1 (da)
CY (1)	CY1121946T1 (da)
DK (1)	DK3149001T3 (da)
EA (1)	EA032050B1 (da)
ES (1)	ES2738695T3 (da)
GT (1)	GT201600249A (da)
HR (1)	HRP20191261T1 (da)
HU (1)	HUE044351T2 (da)
IL (1)	IL247949A0 (da)
LT (1)	LT3149001T (da)
MX (1)	MX373846B (da)
MY (1)	MY182487A (da)
PE (1)	PE20170189A1 (da)
PH (1)	PH12016501862B1 (da)
PL (1)	PL3149001T3 (da)
PT (1)	PT3149001T (da)
RS (1)	RS59039B1 (da)
SG (1)	SG11201607895PA (da)
SI (1)	SI3149001T1 (da)
SV (1)	SV2016005328A (da)
TR (1)	TR201910730T4 (da)
TW (1)	TWI709561B (da)
UY (1)	UY36143A (da)
WO (1)	WO2015181747A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107898791A (zh)	2010-06-03	2018-04-13	药品循环有限责任公司	布鲁顿酪氨酸激酶(btk)抑制剂的应用
CN104704129A (zh)	2012-07-24	2015-06-10	药品循环公司	与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
CN111978319B (zh)	2014-06-27	2023-08-11	诺格拉制药有限公司	芳基受体调制剂及其制备和使用方法
WO2017040304A1 (en)	2015-08-28	2017-03-09	Cornell University	Malt1 inhibitors and uses thereof
WO2017081641A1 (en) *	2015-11-13	2017-05-18	Novartis Ag	Novel pyrazolo pyrimidine derivatives
TWI726969B (zh)	2016-01-11	2021-05-11	比利時商健生藥品公司	用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107296807B (zh) *	2016-04-15	2020-03-20	中国科学院上海生命科学研究院	Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用
WO2018019721A1 (en)	2016-07-26	2018-02-01	Basf Se	Herbicidal pyridine compounds
WO2018019755A1 (en)	2016-07-26	2018-02-01	Basf Se	Herbicidal pyridine compounds
US10662156B2 (en)	2016-07-29	2020-05-26	Toray Industries, Inc.	Guanidine derivative and medical use thereof
EP3490995A1 (en)	2016-07-29	2019-06-05	Lupin Limited	Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2018020474A1 (en) *	2016-07-29	2018-02-01	Lupin Limited	Substituted thiazolo-pyridine compounds as malt1 inhibitors
EP3535254A4 (en)	2016-11-01	2020-06-24	Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC")	COMPOUNDS FOR THE DEGRADATION OF MALT1
TWI795381B (zh)	2016-12-21	2023-03-11	比利時商健生藥品公司	作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3564226B1 (en) *	2016-12-27	2021-06-02	Kao Corporation	Method for producing glyceric acid ester
US10829482B2 (en)	2016-12-27	2020-11-10	Kao Corporation	Method for producing glyceric acid ester
CN109415334B (zh)	2016-12-27	2023-12-08	花王株式会社	1,3-二噁烷-5-酮类的制造方法
US20200009135A1 (en)	2017-02-01	2020-01-09	Medivir Ab	Therapeutic applications of malt1 inhibitors
WO2018159650A1 (ja) *	2017-02-28	2018-09-07	東レ株式会社	グアニジン誘導体及びその医薬用途
WO2018165385A1 (en)	2017-03-08	2018-09-13	Cornell University	Inhibitors of malt1 and uses thereof
WO2018226150A1 (en) *	2017-06-05	2018-12-13	Medivir Aktiebolag	Pyrazolopyrimidine as malt-1 inhibitors
EP3636636B1 (en) *	2017-06-08	2022-07-06	Mitsui Chemicals Agro, Inc.	Pyridone compound and agricultural and horticultural fungicide
JP7271540B2 (ja) *	2017-11-17	2023-05-11	へパジーンセラピューティクス（エイチケイ）リミテッド	Ａｓｋ１阻害剤としての尿素誘導体
MX2020006808A (es)	2017-12-28	2020-12-11	Massachusetts Gen Hospital	Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral.
ES2992431T3 (es) *	2018-06-18	2024-12-12	Janssen Pharmaceutica Nv	Derivados de pirazol como inhibidores de MALT1
WO2019243964A1 (en)	2018-06-18	2019-12-26	Janssen Pharmaceutica Nv	Pyrazole derivatives as malt1 inhibitors
WO2020111087A1 (ja) *	2018-11-28	2020-06-04	武田薬品工業株式会社	複素環化合物
CN109503473B (zh) *	2019-01-07	2020-07-07	上海慧川生物医药科技有限公司	2-甲氧基-3-氨基-5-吡啶硼酸频哪醇酯及其中间体的合成方法
PH12021552018A1 (en)	2019-02-22	2022-09-19	Janssen Pharmaceutica Nv	Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
ES2949871T3 (es) *	2019-04-11	2023-10-03	Janssen Pharmaceutica Nv	Anillos de piridina que contienen derivados como inhibidores de MALT1
WO2021000855A1 (en) *	2019-07-01	2021-01-07	Qilu Regor Therapeutics Inc.	Malt1 inhibitors and uses thereof
CN111138437B (zh) *	2019-12-04	2021-03-05	杭州华东医药集团新药研究院有限公司	取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途
IL294214B2 (en) *	2019-12-27	2026-04-01	Schrodinger Inc	Cyclic compounds and methods for using them
JP7672402B2 (ja)	2020-05-27	2025-05-07	武田薬品工業株式会社	複素環化合物の製造方法
WO2021262969A1 (en)	2020-06-24	2021-12-30	The General Hospital Corporation	Materials and methods of treating cancer
TWI907472B (zh) *	2020-08-05	2025-12-11	匈牙利商羅特格登公司	具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物
AU2021361057A1 (en) *	2020-10-16	2023-06-08	Rarefied Biosciences, Inc.	Malt1 modulators and uses thereof
US20230414629A1 (en) *	2020-11-12	2023-12-28	Monopteros Therapeutics, Inc.	Materials and methods of treating cancer
GB202018412D0 (en)	2020-11-23	2021-01-06	Exscientia Ltd	Malt-1 modulators ii
CN114805037B (zh) *	2021-01-29	2025-08-19	河北圣泰材料股份有限公司	1,2-二甲氧基-1,1,2,2-四氟乙烷的合成方法
WO2023125877A1 (zh)	2021-12-30	2023-07-06	上海翰森生物医药科技有限公司	三并环类衍生物抑制剂、其制备方法和应用
IL314337A (en) *	2022-01-18	2024-09-01	Aurigene Oncology Ltd	Substituted bicyclic heterocycles as malt-1 inhibitors
CN116535424B (zh) *	2022-01-26	2025-04-11	武汉誉祥医药科技有限公司	作为malt1抑制剂的三并环化合物及其药物组合物和应用
WO2023143249A1 (zh) *	2022-01-28	2023-08-03	上海齐鲁制药研究中心有限公司	靶向malt1的蛋白降解化合物
EP4473966A4 (en)	2022-02-02	2026-01-21	Ono Pharmaceutical Co	CANCER TREATMENT AGENT COMPRISING A MALT1 INHIBITOR DRUG AS THE ACTIVE INGREDIENT
WO2023148501A1 (en)	2022-02-03	2023-08-10	C4X Discovery Limited	Heterocyclic derivatives as malt1 inhibitors
AU2024228941A1 (en) *	2023-03-01	2025-08-21	Rarefied Biosciences, Inc.	Compositions and methods for treating malt1 associated diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7517880B2 (en)	1997-12-22	2009-04-14	Bayer Pharmaceuticals Corporation	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20020065296A1 (en)	1999-01-13	2002-05-30	Bayer Corporation	Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
MXPA04007832A (es)	2002-02-11	2005-09-08	Bayer Pharmaceuticals Corp	Aril-ureas con actividad inhibitoria de angiogenesis.
WO2004078163A2 (en)	2003-02-28	2004-09-16	Transform Pharmaceuticals, Inc.	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1505068A4 (en) *	2002-04-23	2008-03-19	Shionogi & Co	PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE
US7196111B2 (en)	2002-06-04	2007-03-27	Schering Corporation	Pyrazolo[1,5a]pyrimidine compounds as antiviral agents
NZ539163A (en) *	2002-09-04	2007-03-30	Schering Corp	Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors
RU2402544C2 (ru) *	2005-01-14	2010-10-27	Си Джи Ай ФАРМАСЬЮТИКАЛЗ, ИНК.	1,3-диарилзамещенные мочевины как модуляторы киназной активности
WO2008063671A2 (en) *	2006-11-20	2008-05-29	Alantos Pharmaceuticals Holding, Inc.	Heterobicyclic metalloprotease inhibitors
US8309523B2 (en) *	2007-11-21	2012-11-13	Vib Vzw	Inhibitors of MALT1 proteolytic activity and uses thereof
GB0821307D0 (en)	2008-11-21	2008-12-31	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN102762208A (zh) *	2009-12-04	2012-10-31	赛林药物股份有限公司	作为ck2抑制剂的吡唑嘧啶和相关杂环
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2465928A1 (en)	2010-12-16	2012-06-20	Academisch Medisch Centrum bij de Universiteit van Amsterdam	Treatment of Th17-mediated diseases
WO2013028263A1 (en) *	2011-08-24	2013-02-28	Glaxosmithkline Llc	Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
CN103570723B (zh) *	2012-07-27	2016-07-13	广西梧州制药（集团）股份有限公司	吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
WO2014078408A1 (en) *	2012-11-13	2014-05-22	Array Biopharma Inc.	Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
EP2935248B1 (en)	2012-12-21	2018-02-28	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
WO2014181287A1 (en)	2013-05-09	2014-11-13	Piramal Enterprises Limited	Heterocyclyl compounds and uses thereof
CN103739550B (zh) *	2014-01-02	2016-06-01	中国药科大学	2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用

2015
- 2015-05-27 ES ES15733899T patent/ES2738695T3/es active Active
- 2015-05-27 AU AU2015265478A patent/AU2015265478B2/en not_active Ceased
- 2015-05-27 MX MX2016015544A patent/MX373846B/es active IP Right Grant
- 2015-05-27 HR HRP20191261TT patent/HRP20191261T1/hr unknown
- 2015-05-27 DK DK15733899.7T patent/DK3149001T3/da active
- 2015-05-27 LT LTEP15733899.7T patent/LT3149001T/lt unknown
- 2015-05-27 CN CN201580020935.9A patent/CN106170489B/zh not_active Expired - Fee Related
- 2015-05-27 SI SI201530825T patent/SI3149001T1/sl unknown
- 2015-05-27 HU HUE15733899 patent/HUE044351T2/hu unknown
- 2015-05-27 RS RS20190905A patent/RS59039B1/sr unknown
- 2015-05-27 WO PCT/IB2015/053975 patent/WO2015181747A1/en not_active Ceased
- 2015-05-27 SG SG11201607895PA patent/SG11201607895PA/en unknown
- 2015-05-27 JP JP2016569068A patent/JP6545197B2/ja not_active Expired - Fee Related
- 2015-05-27 TR TR2019/10730T patent/TR201910730T4/tr unknown
- 2015-05-27 KR KR1020167032664A patent/KR20170007311A/ko not_active Ceased
- 2015-05-27 CR CR20160548A patent/CR20160548A/es unknown
- 2015-05-27 EP EP15733899.7A patent/EP3149001B1/en active Active
- 2015-05-27 CA CA2945077A patent/CA2945077A1/en not_active Abandoned
- 2015-05-27 PL PL15733899T patent/PL3149001T3/pl unknown
- 2015-05-27 US US15/312,321 patent/US9815842B2/en not_active Expired - Fee Related
- 2015-05-27 EA EA201692105A patent/EA032050B1/ru not_active IP Right Cessation
- 2015-05-27 BR BR112016024545A patent/BR112016024545A2/pt active Search and Examination
- 2015-05-27 MY MYPI2016703450A patent/MY182487A/en unknown
- 2015-05-27 PT PT15733899T patent/PT3149001T/pt unknown
- 2015-05-27 PE PE2016002391A patent/PE20170189A1/es unknown
- 2015-05-27 AP AP2016009487A patent/AP2016009487A0/en unknown
- 2015-05-27 TW TW104117061A patent/TWI709561B/zh not_active IP Right Cessation
- 2015-05-27 CU CU2016000181A patent/CU24393B1/es unknown
- 2015-05-28 AR ARP150101686A patent/AR100645A1/es unknown
- 2015-05-28 UY UY0001036143A patent/UY36143A/es not_active Application Discontinuation
2016
- 2016-09-21 IL IL247949A patent/IL247949A0/en unknown
- 2016-09-22 PH PH12016501862A patent/PH12016501862B1/en unknown
- 2016-11-18 CL CL2016002942A patent/CL2016002942A1/es unknown
- 2016-11-28 SV SV2016005328A patent/SV2016005328A/es unknown
- 2016-11-28 GT GT201600249A patent/GT201600249A/es unknown
2017
- 2017-10-11 US US15/729,979 patent/US10442808B2/en not_active Expired - Fee Related
2019
- 2019-07-24 CY CY20191100786T patent/CY1121946T1/el unknown

Also Published As

Publication number	Publication date
EA201692105A1 (ru)	2017-04-28
EA032050B1 (ru)	2019-03-29
LT3149001T (lt)	2019-08-12
SG11201607895PA (en)	2016-12-29
UY36143A (es)	2016-01-08
MY182487A (en)	2021-01-25
CN106170489A (zh)	2016-11-30
KR20170007311A (ko)	2017-01-18
MX2016015544A (es)	2017-03-23
US10442808B2 (en)	2019-10-15
HRP20191261T1 (hr)	2019-10-04
SV2016005328A (es)	2018-06-12
PH12016501862B1 (en)	2019-03-01
SI3149001T1 (sl)	2019-08-30
AU2015265478A1 (en)	2016-10-20
US9815842B2 (en)	2017-11-14
AR100645A1 (es)	2016-10-19
EP3149001B1 (en)	2019-04-24
CN106170489B (zh)	2019-05-03
AP2016009487A0 (en)	2016-10-31
HUE044351T2 (hu)	2019-10-28
AU2015265478B2 (en)	2017-09-14
TR201910730T4 (tr)	2019-08-21
TWI709561B (zh)	2020-11-11
EP3149001A1 (en)	2017-04-05
ES2738695T3 (es)	2020-01-24
US20170121335A1 (en)	2017-05-04
TW201609740A (zh)	2016-03-16
CY1121946T1 (el)	2020-10-14
BR112016024545A2 (pt)	2017-08-15
JP2017516778A (ja)	2017-06-22
PE20170189A1 (es)	2017-03-15
PT3149001T (pt)	2019-07-25
JP6545197B2 (ja)	2019-07-17
RS59039B1 (sr)	2019-08-30
CU24393B1 (es)	2019-04-04
CA2945077A1 (en)	2015-12-03
PL3149001T3 (pl)	2019-10-31
GT201600249A (es)	2018-12-18
US20180030061A1 (en)	2018-02-01
CU20160181A7 (es)	2017-05-10
WO2015181747A1 (en)	2015-12-03
IL247949A0 (en)	2016-11-30
CR20160548A (es)	2017-01-02
PH12016501862A1 (en)	2016-12-19
CL2016002942A1 (es)	2017-07-14
MX373846B (es)	2020-03-26

Publication	Publication Date	Title
DK3149001T3 (da)	2019-07-22	Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
DK3277681T3 (da)	2019-07-29	Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
IL280863A (en)	2021-04-29	Autotaxin inhibitors and uses thereof
DK3221306T3 (da)	2020-01-02	Heteroarylforbindelser som irak-inhibitorer og anvendelser deraf
DK3464271T3 (da)	2020-06-15	Pyrazolderivater som plasma-kallikreininhibitorer
DK3105218T3 (da)	2019-11-04	Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da)	2019-10-14	Cyclopropylaminer som lsd1-inhibitorer
DK3233863T3 (da)	2024-07-15	Kondenserede ringheteroarylforbindelser og anvendelse deraf som trk-hæmmere
LT3303334T (lt)	2021-07-12	Tirozinkinazės inhibitoriai
HUE042335T2 (hu)	2019-06-28	ROR-gamma dihidropirrolopiridin inhibitorai
DK3210977T3 (da)	2019-07-01	Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
BR112016030697A2 (pt)	2018-07-17	inibidores da desmetilase-1 específica da lisina
DK3271349T3 (da)	2019-08-05	Benzimidazolederivater som bromodomain-inhibitorer
DK3143011T3 (da)	2021-05-03	Deutererede heterocykliske forbindelser og deres anvendelse som billeddannende stoffer
DK3766885T3 (da)	2022-08-01	Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer
DK3341379T3 (da)	2019-12-02	EZH2-hæmmere
DK3288944T3 (da)	2019-07-22	Imidazopyrazinoner som pde1-inhibitorer
DK3186242T3 (da)	2021-12-20	Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3214079T3 (da)	2020-09-28	Seks-leddede benzodiazepinderivater som dpp-4-inhibitorer og hvordan de bruges
IL249674B (en)	2019-06-30	Quinolizinone derivatives as pi3k inhibitors
DK3347356T3 (da)	2021-04-26	Tricyclic forbundet pyridin-2-one-derivater og deres anvendelse som brd4-hæmmere
DK3724196T3 (da)	2023-01-16	Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
EP3454852A4 (en)	2020-02-26	PHOSPHOTIDYLINOSITOL 3-KINASES INHIBITORS
DK3277682T3 (da)	2019-07-29	6-morpholinyl-2-pyrazolyl-9h-purinderivater og anvendelse heraf som pi3k- hæmmere
DK3362450T3 (da)	2020-09-14	N1- og N7-substituerede sibirilin-derivater og anvendelse deraf som inhibitorer af cellulær nekroptose